Trials / Completed
CompletedNCT03569371
A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety of INCB054707 in men and women with moderate to severe hidradenitis suppurativa (HS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB054707 | INCB054707 administered once daily orally with water without regard to food for 8 weeks. |
Timeline
- Start date
- 2018-07-17
- Primary completion
- 2019-04-22
- Completion
- 2019-04-22
- First posted
- 2018-06-26
- Last updated
- 2022-09-26
- Results posted
- 2020-05-20
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03569371. Inclusion in this directory is not an endorsement.